AltruBio has secured $225m in an oversubscribed Series B financing round to progress the clinical development of its new immune checkpoint enhancer (ICE) programme.
Financing led by BVF Partners LP, with participation from new investors RA Capital Management, Cormorant Asset Management, Soleus Capital and existing investors aMoon Fund and Blackstone Multi-Asset...
SAN FRANCISCO, May 01, 2024 (GLOBE NEWSWIRE) -- AltruBio Inc. (AltruBio or the Company), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of...
SAN FRANCISCO, Dec. 07, 2023 (GLOBE NEWSWIRE) -- AltruBio Inc. (œAltruBio or œthe Company), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of...
SAN FRANCISCO, Sept. 26, 2023 (GLOBE NEWSWIRE) -- AltruBio Inc. (œAltruBio or œthe Company), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment...
ALTB-268 was well tolerated with no serious adverse events across all subject cohorts ALTB-268 demonstrated substantially greater biological activity than first ICE molecule, ALTB-168, enabling...
SAN FRANCISCO, June 15, 2023 (GLOBE NEWSWIRE) -- AltruBio Inc. (AltruBio or the Company), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of...
SAN FRANCISCO, May 31, 2023 (GLOBE NEWSWIRE) -- AltruBio Inc. (œAltruBio or œthe Company), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of...
SAN FRANCISCO, May 08, 2023 (GLOBE NEWSWIRE) -- AltruBio Inc. (€œAltruBio€ or €œthe Company€), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of...
AltruBio Announces Panels and Presentations at Three March Healthcare Conferences